Monday, October 3, 2022

Friedreich Ataxia: An expanded access program for Elamipretide treatment

Children's Mercy Kansas City / Children’s Mercy Research Institute. 
Full Study Name: SPIES-006
This study is for participants who are 1 to 80 years old and involves the treatment use of Elamipretide through the expanded access program for treatment of Friedreich Ataxia. This is a compassionate use study. Compassionate use studies are those where the drug is not available to the market and the sponsor is providing the drug to the patient without cost to them in hopes that it will help decrease the progression of their disease state.